1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Aldeyra Therapeutics Acquires Helio Vision

M&A Deal Summary

Aldeyra Therapeutics Acquires Helio Vision

On January 29, 2019, Aldeyra Therapeutics acquired life science company Helio Vision

Acquisition Highlights
  • This is Aldeyra Therapeutics’ 1st transaction in the Life Science sector.
  • This is Aldeyra Therapeutics’ 1st transaction in the United States.
  • This is Aldeyra Therapeutics’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2019-01-29
Target Helio Vision
Sector Life Science
Buyer(s) Aldeyra Therapeutics
Deal Type Add-on Acquisition

Target

Helio Vision

Waltham, Massachusetts, United States
Helio Vision, Inc. is a biotechnology company, that develops a therapy for proliferative vitreoretinopathy (PVR), a fibroproliferative disorder that leads to abnormal scarring and blindness after retinal detachment. Helio Vision, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Aldeyra Therapeutics

Lexington, Massachusetts, United States
Category Company
Founded 2004
Sector Life Science
Employees8
DESCRIPTION

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra Therapeutics was founded in 2004 and is incorporated in Lexington, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal